Broadly neutralizing antibody targeting HIV-1 envelope glycoprotein (bnAb targeting HIV-1 Env)

Broadly neutralizing antibodies (bnAbs) are a class of human monoclonal antibodies capable of binding and neutralizing diverse strains of HIV-1 by targeting conserved epitopes on the virus's envelope glycoprotein complex (Env). Env is a trimeric complex composed of gp120 and gp41 subunits; it mediates viral entry by binding the CD4 receptor and a coreceptor (CCR5 or CXCR4) on host immune cells, followed by fusion of viral and host membranes[1][3][4][6][7]. The conserved regions targeted by bnAbs include the CD4-binding site, V2/V3 loops, the membrane-proximal external region (MPER) of gp41, and glycan patches of gp120[6]. These antibodies act by preventing viral attachment, blocking post-attachment conformational changes, or inhibiting membrane fusion, and are seen as promising leads for both HIV therapy and vaccine development[6][3][4]. However, HIV-1's high sequence variability and rapid mutation rate pose significant challenges for vaccine design and long-term therapeutic efficacy[1][6]. The entry "broadly neutralizing antibodies targeting HIV-1 Env" refers to antibodies as *therapeutics* rather than a molecular target, and the actual target in this context is the HIV-1 envelope glycoprotein (Env).

Other names

Broadly neutralizing anti-HIV-1 antibodiesbnAbs targeting HIV-1Anti-HIV-1 Env broadly neutralizing antibodiesAnti-gp120/gp41 broadly neutralizing antibodies

Block HIV-1 binding to host cell receptors (CD4 and CCR5/CXCR4) - Inhibit conformational changes of Env required for membrane fusion - Steric hindrance or sequestration of conserved regions on Env